⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL798034 | 1.00 | — | — | |
| SCHEMBL1104694 | 1.00 | — | — | |
| SCHEMBL17403819 | 0.92 | — | — | |
| SCHEMBL17403818 | 0.92 | — | — | |
| SCHEMBL9883697 | 0.92 | — | — | |
| SCHEMBL14749887 | 0.90 | EPHX1 (0.31) | — | |
| SCHEMBL19565524 | 0.85 | — | — | |
| SCHEMBL19565525 | 0.85 | — | — | |
| SCHEMBL14330213 | 0.85 | — | — | |
| SCHEMBL18419228 | 0.83 | NOS2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-11858916-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11802121-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230295131-A1 | INHIBITORS OF RHO-ASSOCIATED COILED-COIL KINASE | ANGION BIOMEDICA CORP. | 2023-09-21 | — | — | US | disclosed |
| US-20230295131-A1 | INHIBITORS OF RHO-ASSOCIATED COILED-COIL KINASE | ANGION BIOMEDICA CORP. | 2023-09-21 | — | — | US | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11708320-B2 | Environmentally-friendly hydroazidation of olefins | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
| US-20100190762-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100190762-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-7718683-B2 | Triazolyl phenyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718683-B2 | Triazolyl phenyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-20090258885-A1 | Diphenylmethane Derivatives as Inhibitors of Leukotriene Biosynthesis | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-7399862-B2 | 5-HT4 receptor agonist compounds | THERAVANCE, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-20080039465-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080039465-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20060100236-A1 | For therapy of disorder of reduced motility of gastrointestinal tract, chronic constipation, functional dyspepsia, delayed gastric emptying, gastroesophageal reflux disease, gastroparesis, diabetic and iodiopathic gastropathy, post-operative ileus, intestinal pseudo-obstruction, irritable bowel syndrome | THERAVANCE, INC. (US) | 2006-05-11 | — | — | US | disclosed |